Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.79 USD | -5.00% | -4.65% | -16.24% |
May. 07 | Transcript : Pediatrix Medical Group, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Earnings Flash (MD) PEDIATRIX MEDICAL GROUP Posts Q1 Revenue $495.1M, vs. Street Est of $500.4M | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.53 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.24% | 679M | B | ||
+19.22% | 85.64B | C+ | ||
-27.14% | 70.63B | B- | ||
+4.65% | 27.05B | C+ | ||
-6.23% | 17.97B | B | ||
+1.60% | 17.58B | A- | ||
+3.30% | 15.64B | A- | ||
+7.44% | 13.55B | B- | ||
+9.91% | 13.41B | A- | ||
+73.32% | 13.18B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MD Stock
- Ratings Pediatrix Medical Group, Inc.